JP2023536269A5 - - Google Patents

Info

Publication number
JP2023536269A5
JP2023536269A5 JP2023506247A JP2023506247A JP2023536269A5 JP 2023536269 A5 JP2023536269 A5 JP 2023536269A5 JP 2023506247 A JP2023506247 A JP 2023506247A JP 2023506247 A JP2023506247 A JP 2023506247A JP 2023536269 A5 JP2023536269 A5 JP 2023536269A5
Authority
JP
Japan
Prior art keywords
protein
complex according
human
complex
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023506247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044052 external-priority patent/WO2022026917A1/en
Publication of JP2023536269A publication Critical patent/JP2023536269A/ja
Publication of JP2023536269A5 publication Critical patent/JP2023536269A5/ja
Pending legal-status Critical Current

Links

JP2023506247A 2020-07-31 2021-07-30 ワクチン組成物及びその使用方法 Pending JP2023536269A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059845P 2020-07-31 2020-07-31
US63/059,845 2020-07-31
PCT/US2021/044052 WO2022026917A1 (en) 2020-07-31 2021-07-30 Vaccine compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023536269A JP2023536269A (ja) 2023-08-24
JP2023536269A5 true JP2023536269A5 (enExample) 2024-08-05

Family

ID=80036791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506247A Pending JP2023536269A (ja) 2020-07-31 2021-07-30 ワクチン組成物及びその使用方法

Country Status (7)

Country Link
US (1) US20230277646A1 (enExample)
EP (1) EP4188437A4 (enExample)
JP (1) JP2023536269A (enExample)
CN (1) CN116457366A (enExample)
AU (1) AU2021319206A1 (enExample)
CA (1) CA3190428A1 (enExample)
WO (1) WO2022026917A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188437A4 (en) * 2020-07-31 2024-09-25 The Board of Trustees of the Leland Stanford Junior University Vaccine compositions and methods of use thereof
WO2023168541A1 (en) * 2022-03-09 2023-09-14 Shenzhen Genius Biotech Service Co., Ltd. Chitosan nanoparticles (cnps) and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US8815295B1 (en) * 2011-12-22 2014-08-26 Alabama State University Anti respiratory syncytial virus peptide functionalized gold nanoparticles
EP3024936B1 (en) * 2013-07-25 2019-09-04 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2017053720A1 (en) * 2015-09-25 2017-03-30 Tarveda Therapeutics, Inc. RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
CA3043775A1 (en) * 2016-12-06 2018-06-14 Universite Laval Ultrastable gold nanoparticles for drug delivery applications and synthesis thereof
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
EP4188437A4 (en) * 2020-07-31 2024-09-25 The Board of Trustees of the Leland Stanford Junior University Vaccine compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
Lin et al. Restriction of H1N1 influenza virus infection by selenium nanoparticles loaded with ribavirin via resisting caspase-3 apoptotic pathway
Huo et al. Pre-treatment with zirconia nanoparticles reduces inflammation induced by the pathogenic H5N1 influenza virus
JP2023536269A5 (enExample)
CN102579588B (zh) 清热解表胶囊
JP2010500291A5 (enExample)
JP2022537178A5 (enExample)
JP2013537426A5 (enExample)
CN106659805A (zh) 通过miRNA抑制埃博拉病毒的方法
JP2017529398A5 (enExample)
CN102335375B (zh) 一种用于治疗肺部疾病的药物组合物及其应用
TWI884297B (zh) mRNA奈米膠囊及其用於製備抗病毒藥物的用途
JP2015515974A5 (enExample)
CN116459295A (zh) 一种肺炎清化方及其应用
JP2023518376A5 (enExample)
EP2571367B1 (en) Breast cancer therapy using an engineered respiratory syncytial virus
CN103127361A (zh) 一种治疗小儿喘息性肺炎的中药制剂
Ghasemzad et al. The nano-based theranostics for respiratory complications of COVID-19
KR20200136430A (ko) 점액 층을 가로지르는 마이크로/나노입자의 전위를 향상시키기 위한 알지네이트 올리고머의 용도
WO2022150709A1 (en) Compositions and methods for treating viral infection
CN102836266A (zh) 一种治疗小儿支原体肺炎的口服液
Mustafa et al. Nanobodies as Spray and Aerosol Particles: A Breakthrough in Treating Respiratory Viral Infections
JP2010189301A (ja) 新型インフルエンザ感染症に対する医薬組成物およびその利用
US20240075012A1 (en) Compositions and methods for treating viral infection
US20220401472A1 (en) Compositions for prevention and treatment of rsv and coronavirus infection
Stass et al. Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD